Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples

Казарян, А.В.; Blyuss, Oleg; Metodieva, Gergana; Gentry‐Maharaj, Aleksandra; Ryan, Andy; Kiseleva, Elena M.; Prytomanova, O. M.; Jacobs, Ian; Widschwendter, Martin; Menon, Usha; Timms, John F.

doi:10.1038/bjc.2016.433

Cited by 99 publications

(64 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Yumi Kim, et al Mastocheck for Screening of Breast Cancer mended blood test for the diagnosis of breast cancer, its value as a diagnostic or prognostic factor for various tumor markers based on blood tests is being studied [8][9][10][11]. We have developed a blood marker for breast cancer diagnosis using proteomic techniques through numerous experiments over 10 years using tissue, blood, and cell samples.…”

mentioning

confidence: 99%

Efficacy of Mastocheck for Screening of Early Breast Cancer: Comparison with Screening Mammography

et al. 2019

View full text Add to dashboard Cite

This study was designed to verify the effectiveness of Mastocheck, a new diagnostic tool developed with proteomics techniques using plasma proteins. In addition, checked the current state of mammography used for breast cancer screening. Methods: A total of 305 cases were analyzed (normal 122, breast cancer 183) and used for validation after Mastocheck development. First, screening mammograms of normal patients and pre-diagnosis mammography of cancer patients were reviewed retrospectively. The results were compared with Mastocheck, a newly developed blood test. Imaging tests were blinded and analyzed by dividing the readings of breast specialists and non-breast specialists among radiologists. We confirmed how much better the results would be if only the mammography was used and if both tests were used together. Results: The sensitivity, specificity, and accuracy of mammography alone, reviewed by non-breast specialists among radiologists, were 63.0%, 85.7%, and 71.3%, respectively. In dense breasts, the values were 59.2%, 84.8% and 69.0%, which were too low to be considered interpretable. The sensitivity, specificity and accuracy of the test was 93.9%, 83.8%, and 90.2% when using mammography and Mastocheck together. From these results, an improvement in sensitivity of about 30% and an improvement in accuracy of about 15% or more in concomitant use than mammography alone can be seen. Conclusion: Mastocheck can be widely used for screening breast cancer, especially in dense breasts, patients with low accuracy in mammography, and patients with mammography side effects. In addition, it has the advantage of increasing the diagnosis rate when used with mammography, the current screening method of choice.

show abstract

mentioning

confidence: 99%

Efficacy of Mastocheck for Screening of Early Breast Cancer: Comparison with Screening Mammography

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Despite the usefulness of Mammography in the diagnosis of breast cancer, it showed a limited sensitivity for the detection of tumors in dense breast tissue (Boyd et al, 2007). Therefore, there is an urgent need for biochemical and histological markers that can be used in the early diagnosis and prediction of the disease outcome in addition to the need for marker that provides a prognostic information to the clinician for treatment strati ication, so, various markers either biochemical or immunohistochemical were discovered and tested widely for this purpose (Kazarian et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

The role of Ghrelin Receptor Expression in the Diagnosis of breast cancer

Ajeed

Alwakeel

Abdul‐Rasheed

2020

ijrps

View full text Add to dashboard Cite

To determine the possible role of the assessment of Ghrelin receptor expression in breast tissues as a tool for the diagnosis of breast cancer and differentiate it from a benign breast tumor. A case-control study was done on 60 female patients with breast cancer and 60 female patients with benign breast tumors (Fibroadenoma) who were recruited from Al Imamain Al-Kadhemain Medical City and Oncology teaching Hospital, Baghdad, Iraq between May 2018 and December 2018. Immunohistochemical staining was done on the breast tissue samples obtained from patients and compared with the control group, which comprised 75 ibrocystic tissue samples obtained from age, BMI and sex-matched females. The degree of Ghrelin Receptor expression was determined immunohistochemically. The expression of Ghrelin receptors in breast malignant tumor tissues was higher than that in benign breast tumor tissues and controls, in addition to that, results obtained from all groups revealed that Ghrelin receptor intensity and its expression proportion were strongly and signi icantly associated with the type of tissues. The expression of the Ghrelin receptor can be considered as a highly signi icant immunohistochemical marker for the detection of breast tumors and for the differentiation between both types of tumors; benign and malignant.

show abstract

“…However the benefit for women aged 40 to 49 is uncertain (5), and risk of false positive results and overdiagnosis are of concern (2, 4). Given that screening for specific cancers with certain noninvasive blood tests, such as CA125 for detecting ovarian cancer, could increase patient compliance and has already shown relatively good diagnostic performance (6,7), there also might be a possible approach for non-invasive early detection and/or risk stratification of breast cancer (7).…”

Section: Introductionmentioning

confidence: 99%

Whole-Blood DNA Methylation Markers in Early Detection of Breast Cancer: A Systematic Literature Review

Guan

Ćuk

et al. 2019

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Whole-blood DNA methylation markers have been suggested as potential biomarkers for early detection of breast cancer. We conducted a systematic review of the literature on whole-blood DNA methylation markers for breast cancer detection. PubMed and ISI Web of Knowledge were searched up to May 29, 2018. Overall, 33 studies evaluating 355 markers were included. The diagnostic value of most individual markers was relatively modest, with only six markers showing sensitivity >40% at specificity >75% [only 2 (HYAL2 and S100P) were independently validated]. Although relatively strong associations (OR 0.5 or OR 2) with breast cancer were reported for 14 markers, most of them were not independently validated. Two prospective studies performed epigenome-wide association analysis and identified 276 CpG sites related to breast cancer risk, but no overlap was observed between CpGs reported from these two studies. Five studies incorporated individual markers as panels, but only two of them used a test-validation approach. In conclusion, so far detected methylation markers are insufficient for breast cancer early detection, but markers or marker-combinations may be useful for breast cancer risk stratification. Utilizing high-throughput methods of methylation quantification, future studies should focus on further mining informative methylation markers and derivation of enhanced multimaker panels with thorough external validation ideally in prospective settings. Abbreviation: ref., reference. a Model adjusted for age, family history, age at menarche, parity, menopausal status, and body mass index. b No information for model covariates adjustment. c Model adjusted for age, family history, body mass index, and physical activity. d Model adjusted for age, race, family history of breast cancer, study site, menopausal status, parity, and age at menarche. e Crude odds ratio. f Model adjusted for menopausal status, age, and weight. g Statistical significance for OR.Guan et al.

show abstract

Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples

Cited by 99 publications

References 36 publications

Efficacy of Mastocheck for Screening of Early Breast Cancer: Comparison with Screening Mammography

Efficacy of Mastocheck for Screening of Early Breast Cancer: Comparison with Screening Mammography

The role of Ghrelin Receptor Expression in the Diagnosis of breast cancer

Whole-Blood DNA Methylation Markers in Early Detection of Breast Cancer: A Systematic Literature Review

Contact Info

Product

Resources

About